• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱癌患者的生存率、治疗延迟评估、外科医生类型及治疗方式。

Survival with bladder cancer, evaluation of delay in treatment, type of surgeon, and modality of treatment.

作者信息

Gulliford M C, Petruckevitch A, Burney P G

机构信息

Department of Public Health Medicine, United Medical School, London.

出版信息

BMJ. 1991 Aug 24;303(6800):437-40. doi: 10.1136/bmj.303.6800.437.

DOI:10.1136/bmj.303.6800.437
PMID:1912834
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1670565/
Abstract

OBJECTIVE

To determine whether length of delay before treatment; specialty and grade of the surgeon; and use made of surgery, radiotherapy, and chemotherapy influenced the survival of patients with cancer of the bladder, after adjusting for case severity.

DESIGN

Retrospective cohort study.

SETTING

South East and South West Thames health regions.

PATIENTS

609 men aged under 75 resident in the South Thames regions who had been registered as new cases of bladder cancer in 1982, 35 of whom were excluded, leaving 574 eligible patients. Analysis was based on 75% retrieval rate for case notes.

MAIN OUTCOME MEASURES

Duration of survival from date of diagnosis of the bladder tumour.

RESULTS

10 prognostic variables were used to adjust for case severity. The median delay from referral to first treatment was 48 (interquartile range 27-84) days. Treatment after a short delay was associated with shorter survival because of the early treatment of more severe cases. Consultants treated 68% of patients, trainee surgeons treated less severe cases. Initial treatment was by a urologist in 67% of cases, but the specialty of the surgeon was not associated with prognosis. The associations of radiotherapy, cystectomy, and systemic chemotherapy with survival were interpreted in terms of selection bias as well as therapeutic effect.

CONCLUSION

Case severity was the most important influence on survival and influenced length of delay before treatment, grade and specialty of the surgeon, and main treatment allocation. After adjusting for case severity variations in these processes of care were not strongly associated with variations in survival.

摘要

目的

在对病例严重程度进行校正后,确定治疗前的延迟时间、外科医生的专业和级别以及手术、放疗和化疗的使用是否会影响膀胱癌患者的生存率。

设计

回顾性队列研究。

地点

泰晤士河南部和西南部健康区域。

患者

居住在泰晤士河南部地区的609名75岁以下男性,他们在1982年被登记为膀胱癌新病例,其中35人被排除,剩下574名符合条件的患者。分析基于病例记录75%的检索率。

主要观察指标

从膀胱肿瘤诊断日期起的生存时间。

结果

使用10个预后变量对病例严重程度进行校正。从转诊到首次治疗的中位延迟时间为48天(四分位间距27 - 84天)。延迟时间短的治疗与较短的生存期相关,因为更严重的病例得到了早期治疗。顾问医生治疗了68%的患者,实习外科医生治疗病情较轻的病例。67%的病例初始治疗由泌尿科医生进行,但外科医生的专业与预后无关。放疗、膀胱切除术和全身化疗与生存的关联在选择偏倚以及治疗效果方面得到了解释。

结论

病例严重程度是对生存的最重要影响因素,并且影响治疗前的延迟时间、外科医生的级别和专业以及主要治疗分配。在对病例严重程度进行校正后,这些医疗过程中的差异与生存差异没有强烈关联。

相似文献

1
Survival with bladder cancer, evaluation of delay in treatment, type of surgeon, and modality of treatment.膀胱癌患者的生存率、治疗延迟评估、外科医生类型及治疗方式。
BMJ. 1991 Aug 24;303(6800):437-40. doi: 10.1136/bmj.303.6800.437.
2
[Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].[根治性膀胱切除术治疗浸润性膀胱癌的结果,特别提及根据尿流改道类型的预后因素和生活质量]
Ann Acad Med Stetin. 2000;46:217-29.
3
Contributions of incidence and case fatality to mortality from bladder cancer in the south Thames Regions.发病率和病死率对泰晤士河南部地区膀胱癌死亡率的影响。
J Epidemiol Community Health. 1992 Aug;46(4):387-9. doi: 10.1136/jech.46.4.387.
4
Treatment delay and prognosis in invasive bladder cancer.浸润性膀胱癌的治疗延迟与预后
J Urol. 2005 Nov;174(5):1777-81; discussion 1781. doi: 10.1097/01.ju.0000177521.72678.61.
5
Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time.膀胱癌根治性切除术的条件生存:随时间变化的患者风险特征证据。
Eur Urol. 2014 Aug;66(2):361-70. doi: 10.1016/j.eururo.2013.09.050. Epub 2013 Oct 9.
6
Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network.膀胱小细胞癌:对东安格利亚癌症网络治疗及生存情况的15年回顾性分析
BJU Int. 2009 Mar;103(6):747-52. doi: 10.1111/j.1464-410X.2008.08241.x. Epub 2008 Dec 5.
7
[Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].[辅助化疗治疗膀胱pT3b浸润性肿瘤的预后]
Prog Urol. 1998 Dec;8(6):1007-11.
8
Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach.新辅助化疗后肌层浸润性膀胱癌根治性切除术的高效实施:多学科方法。
Cancer. 2012 Jan 1;118(1):44-53. doi: 10.1002/cncr.26240. Epub 2011 May 19.
9
The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.肌层浸润性膀胱癌诊断与根治性膀胱切除术之间的时间间隔对分期和生存的影响:一项荷兰癌症登记处分析。
Urol Oncol. 2016 Apr;34(4):166.e1-6. doi: 10.1016/j.urolonc.2015.11.006. Epub 2015 Dec 15.
10
The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?卡介苗治疗非肌层浸润性膀胱癌后复发的同步放化疗结果:是否总是需要立即进行膀胱切除术?
BJU Int. 2009 Jul;104(2):179-83. doi: 10.1111/j.1464-410X.2008.08299.x. Epub 2008 Dec 23.

引用本文的文献

1
A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond.关于膀胱癌和上尿路尿路上皮癌手术延迟的系统评价和荟萃分析:对 COVID-19 大流行及以后的启示。
Front Surg. 2022 Oct 4;9:879774. doi: 10.3389/fsurg.2022.879774. eCollection 2022.
2
Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis.癌症诊断工具辅助初级保健决策:混合方法系统评价和成本效益分析。
Health Technol Assess. 2020 Nov;24(66):1-332. doi: 10.3310/hta24660.
3
Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer.术前等待时间对临床 II/III 期胃癌患者生存的影响。
Gastric Cancer. 2019 Jul;22(4):864-872. doi: 10.1007/s10120-018-00910-y. Epub 2018 Dec 10.
4
Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review.有症状癌症的诊断和治疗时间增加是否与较差的预后相关?系统评价。
Br J Cancer. 2015 Mar 31;112 Suppl 1(Suppl 1):S92-107. doi: 10.1038/bjc.2015.48.
5
Are alarm symptoms predictive of cancer survival?: population-based cohort study.警示症状能否预测癌症生存率?基于人群的队列研究。
Br J Gen Pract. 2013 Dec;63(617):e807-12. doi: 10.3399/bjgp13X675197.
6
Survival analysis of patients with bladder cancer, life table approach.膀胱癌患者的生存分析,生命表法。
J Midlife Health. 2012 Jul;3(2):88-92. doi: 10.4103/0976-7800.104468.
7
Management of concomitant cancer and abdominal aortic aneurysm.同时性癌症与腹主动脉瘤的处理。
Cardiol Res Pract. 2011 Apr 19;2011:516146. doi: 10.4061/2011/516146.
8
An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec.魁北克省膀胱癌根治性膀胱切除术术前延迟情况分析。
Can Urol Assoc J. 2008 Apr;2(2):102-8. doi: 10.5489/cuaj.482.
9
How will the two-weeks-wait rule affect delays in management of urological cancers?两周等待规则将如何影响泌尿系统癌症治疗的延迟?
J R Soc Med. 2003 Aug;96(8):398-9. doi: 10.1177/014107680309600809.
10
The reliability of cancer registry records.癌症登记记录的可靠性。
Qual Health Care. 1996 Jun;5(2):120-1.

本文引用的文献

1
DELAY IN TREATING BLADDER TUMOURS.膀胱肿瘤治疗的延误
Lancet. 1965 Aug 14;2(7407):332-4. doi: 10.1016/s0140-6736(65)90298-9.
2
Regional differences in survival from cancer.癌症生存率的地区差异。
Community Med. 1981 Nov;3(4):291-7.
3
Presenting symptoms, treatment delay and survival in bladder cancer.膀胱癌的症状表现、治疗延误与生存率
Scand J Urol Nephrol. 1983;17(2):163-7. doi: 10.3109/00365598309180162.
4
T3 bladder cancer: salvage rather than elective cystectomy after radiotherapy.T3期膀胱癌:放疗后采用挽救性而非选择性膀胱切除术。
Urology. 1984 Oct;24(4):315-20. doi: 10.1016/0090-4295(84)90199-7.
5
Geographical variation in mortality from conditions amenable to medical intervention in England and Wales.英格兰和威尔士可通过医疗干预改善病情的疾病死亡率的地区差异。
Lancet. 1983 Mar 26;1(8326 Pt 1):691-6. doi: 10.1016/s0140-6736(83)91981-5.
6
Prognostic factors in superficial bladder cancer.浅表性膀胱癌的预后因素
Prog Clin Biol Res. 1986;221:257-69.
7
Hospital inpatient mortality. Is it a predictor of quality?医院住院患者死亡率。它是质量的预测指标吗?
N Engl J Med. 1987 Dec 24;317(26):1674-80. doi: 10.1056/NEJM198712243172626.
8
Adjusted hospital death rates: a potential screen for quality of medical care.调整后的医院死亡率:医疗质量的潜在筛查指标。
Am J Public Health. 1987 Sep;77(9):1162-6. doi: 10.2105/ajph.77.9.1162.
9
Selecting initial therapy for bladder cancer.选择膀胱癌的初始治疗方法。
Cancer. 1987 Aug 1;60(3 Suppl):502-13. doi: 10.1002/1097-0142(19870801)60:3+<502::aid-cncr2820601512>3.0.co;2-w.
10
Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report.膀胱癌T3期的辅助化疗。一项前瞻性试验:初步报告。
Br J Urol. 1988 Dec;62(6):558-64. doi: 10.1111/j.1464-410x.1988.tb04426.x.